Ibyerekeye-kanseri / kuvura / ivuriro-ibigeragezo / testicular-kanseri
Igeragezwa rya Clinical yo kuvura Kanseri Yumuti
Ikigeragezo 1-4 cya 4
Nivolumab na Ipilimumab mu kuvura abarwayi bafite ibibyimba bidasanzwe
Iki cyiciro cya II cyikigereranyo cyiga nivolumab na ipilimumab mukuvura abarwayi bafite ibibyimba bidasanzwe. Immunotherapy hamwe na antibodiyite za monoclonal, nka nivolumab na ipilimumab, irashobora gufasha sisitemu yumubiri yumubiri gutera kanseri, kandi irashobora kubangamira ubushobozi bwingirabuzimafatizo yibibyimba gukura no gukwirakwira. Uru rubanza rwandikisha abitabiriye amahugurwa akurikira hashingiwe ku miterere: 1. Ibibyimba bya Epiteliyale yo mu cyuho cyo mu mazuru, sinus, nasofarynx: A) Kanseri y'udukoko twitwa kanseri yo mu mazuru, sinus, na nasofarynx na trachea (ukuyemo kanseri yo mu kanwa, izuru [NPC] , na kanseri y'utugingo ngengabuzima twa kanseri yo mu mutwe no mu ijosi [SCCHN]) B) Adenocarcinoma n'ibihinduka byo mu kiziba cy'amazuru, sinus, na nasofarynx (bifunze kugeza kuri 07/27/2018) 2. Ibibyimba bya Epiteliyale ya glande nini y'amacandwe (bifunze kugeza kuri 03 / 20/2018) 3. Amacandwe yo mu bwoko bwa salivary yibibyimba byumutwe nijosi, iminwa, esofagusi, igifu, trachea nibihaha, amabere nahandi hantu (hafunzwe kugirango habeho) 4. Kanseri idatandukanijwe ya gastrointestinal (GI) 5. Adenocarcinoma ifite amara mato mato (ifunze kugeza kubarwa 05/10/2018) 6. Kanseri y'utugingo ngengabuzima twa kanseri ya GI (amara mato mato, igifu, urukiramende, pancreas) (ifunze kugeza ku ya 10/17/2018) 7. Fibromixoma na mucinous adenocarcinoma yo mu rwego rwo hasi (pseudomixoma peritonei) ya umugereka na ovary (bifunze kugeza kuri 03/20/2018) 8. Ibibyimba bidasanzwe byitwa pancreatic kanseri harimo kanseri ya acinar selile, mucinous cystadenocarcinoma cyangwa cystadenocarcinoma serous. Indwara ya pancreatic adenocarcinoma ntabwo yemerewe 9. Intrahepatic cholangiocarcinoma (ifunze kugeza kuri 03/20/2018) 10. Indwara ya cholangiocarcinoma idasanzwe hamwe n'ibibyimba byo mu mara (bifunze kugeza ku ya 03/20/2018) 11. Kanseri ya Sarcomatoide y'ibihaha 12. Bronchoalveolar carcinoma ibihaha. Iyi ndwara ubu nanone yitwa adenocarcinoma mu mwanya, adenocarcinoma yibasiye cyane, lepidic yiganjemo adenocarcinoma, cyangwa adenocarcinoma yibasira 13. Ibibyimba bitari epiteliyale yintanga ngore: A) Ikibyimba cya selile ya ovary B) Mullerian ivanze na adenosarcoma. kumenyekanisha 03/30/2018) 14. Ikibyimba cya Trophoblastique: A) Choriocarcinoma (ifunze kugeza kuri accrual) 15. Kanseri y'inzibacyuho y'inzibacyuho itari iy'impyiko, pelvis, ureter, cyangwa uruhago (ifunze kugeza ibarwa) 16. Ikibyimba cy'akagari ka testes hamwe na kanseri ya mikorobe idasanzwe: A) Seminoma na kanseri yimibonano mpuzabitsina B) Ikibyimba kitari seminomatike C) Teratoma hamwe nimpinduka mbi (ifunze kuri accrual) 17.
Aho uherereye: 895
Igenzura rifatika, Bleomycin, Carboplatine, Etoposide, cyangwa Cisplatine mu kuvura abarwayi b’abana n’abakuze bafite ibibyimba byo mu Budage Iki cyiciro cya III cyiga uburyo igenzura rikora neza, bleomycine, karboplatine, etoposide, cyangwa cisplatine ikora mu kuvura ibibyimba by’abana bato n’abantu bakuru. . Igenzura rifatika rishobora gufasha abaganga gukurikirana ingingo zifite ibibyimba biterwa na mikorobe nkeya nyuma yo kuvaho. Ibiyobyabwenge bikoreshwa muri chimiotherapie, nka bleomycine, karboplatine, etoposide, na cisplatine, bikora muburyo butandukanye bwo guhagarika imikurire ya selile yibibyimba, haba mukwica selile, kubabuza gutandukana, cyangwa kubabuza gukwirakwira. Aho uherereye: ahantu 460
Inotuzumab Ozogamicin na Chimiotherapie ya Induction nyuma yo kuvura abarwayi bafite ibyago byinshi B-BYOSE, bivanze na Fenotype ivanze na Leukemia ikaze, na B-LLy
Iki cyiciro cya III cyigeragezwa niba inotuzumab ozogamicin yongewe kumiti ya chimiotherapie nyuma yinduction kubarwayi bafite ibyago byinshi-B-selile Acute Lymphoblastique Leukemia (B-BYOSE) bitezimbere ibisubizo. Iki kigeragezo kandi cyiga ku byavuye mu barwayi bafite fenotipike ikaze ya leukemia (MPAL), na B-lymphoblastique lymphoma (B-LLy) iyo ivuwe hamwe n’ubuvuzi bwose nta inotuzumab ozogamicin. Inotuzumab ozogamicin ni antibody ya monoclonal, yitwa inotuzumab, ifitanye isano na chimiotherapie yitwa calicheamicin. Inotuzumab ifata kanseri ya kanseri muburyo bugenewe kandi itanga calicheamicine kugirango ibice. Indi miti ikoreshwa muburyo bwa chimiotherapie, nka cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, na pegaspargase ikora muburyo butandukanye bwo guhagarika imikurire ya selile ya kanseri, haba mu kwica selile, kubabuza gutandukana, cyangwa kubabuza gukwirakwira. Iki kigeragezo kandi kiziga ku byavuye mu barwayi bafite fenotipike ikaze ya leukemia (MPAL) ikwirakwiza lymphoma B lymphoblastique B (B-LLy) igihe ivuwe hamwe na chimiotherapie ishobora guteza ibyago byinshi. Intego rusange yubu bushakashatsi ni ukumva niba kongeramo inotuzumab ozogamicin kurwego rwubuvuzi bwa chimiotherapie ikomeza cyangwa igateza imbere ibisubizo muri Risk B-selile Acute Lymphoblastique Leukemia (HR B-ALL). Igice cya mbere cyubushakashatsi kirimo ibyiciro bibiri byambere byo kuvura: Kwinjiza no guhuriza hamwe. Iki gice kizakusanya amakuru kuri leukemia, hamwe ningaruka zokuvurwa kwambere, murwego rwo gushyira abarwayi mumatsinda yo kuvura nyuma yo guhuriza hamwe. Ku gice cya kabiri cy’ubu bushakashatsi, abarwayi bazahabwa ibisigaye bya chimiotherapie (kubungabunga by'agateganyo I, gutinda gukomera, kubungabunga by'agateganyo II, kubungabunga), hamwe n’abarwayi bamwe na bamwe bahisemo kwakira inotuzumab. Izindi ntego z’ubu bushakashatsi zirimo gukora iperereza niba kuvura abagabo n’igitsina gore igihe kimwe cya chimiotherapie bikomeza ibisubizo ku bagabo bavuwe mbere y’umwaka w’inyongera ugereranije n’abakobwa, ndetse no gusuzuma uburyo bwiza bwo gufasha abarwayi kubahiriza umunwa imiti ya chimiotherapie. Hanyuma, ubu bushakashatsi buzaba ubwambere mugukurikirana ibyavuye mumasomo akwirakwizwa na B-selile Lymphoblastique Leukemia (B LLy) cyangwa ivangwa rya Phenotype Acute Leukemia (MPAL) mugihe ivuwe na B-BYOSE chimiotherapie. abarwayi bazakira ibisigaye bya chimiotherapie (kubungabunga by'agateganyo I, gutinda gukomera, kubungabunga by'agateganyo II, kubungabunga), hamwe nabarwayi bamwe bahisemo kwakira inotuzumab. Izindi ntego z’ubu bushakashatsi zirimo gukora iperereza niba kuvura abagabo n’igitsina gore igihe kimwe cya chimiotherapie bikomeza ibisubizo ku bagabo bavuwe mbere y’umwaka w’inyongera ugereranije n’abakobwa, ndetse no gusuzuma uburyo bwiza bwo gufasha abarwayi kubahiriza umunwa imiti ya chimiotherapie. Hanyuma, ubu bushakashatsi buzaba ubwambere mugukurikirana ibyavuye mumasomo akwirakwizwa na B-selile Lymphoblastique Leukemia (B LLy) cyangwa ivangwa rya Phenotype Acute Leukemia (MPAL) mugihe ivuwe na B-BYOSE chimiotherapie. abarwayi bazakira ibisigaye bya chimiotherapie (kubungabunga by'agateganyo I, gutinda gukomera, kubungabunga by'agateganyo II, kubungabunga), hamwe nabarwayi bamwe bahisemo kwakira inotuzumab. Izindi ntego z’ubu bushakashatsi zirimo gukora iperereza niba kuvura abagabo n’igitsina gore igihe kimwe cya chimiotherapie bikomeza ibisubizo ku bagabo bavuwe mbere y’umwaka w’inyongera ugereranije n’abakobwa, ndetse no gusuzuma uburyo bwiza bwo gufasha abarwayi kubahiriza umunwa imiti ya chimiotherapie. Hanyuma, ubu bushakashatsi buzaba ubwambere mugukurikirana ibyavuye mumasomo akwirakwizwa na B-selile Lymphoblastique Leukemia (B LLy) cyangwa ivangwa rya Phenotype Acute Leukemia (MPAL) mugihe ivuwe na B-BYOSE chimiotherapie. Izindi ntego z’ubu bushakashatsi zirimo gukora iperereza niba kuvura abagabo n’igitsina gore igihe kimwe cya chimiotherapie bikomeza ibisubizo ku bagabo bavuwe mbere y’umwaka w’inyongera ugereranije n’abakobwa, ndetse no gusuzuma uburyo bwiza bwo gufasha abarwayi kubahiriza umunwa imiti ya chimiotherapie. Hanyuma, ubu bushakashatsi buzaba ubwambere mugukurikirana ibyavuye mumasomo akwirakwizwa na B-selile Lymphoblastique Leukemia (B LLy) cyangwa ivangwa rya Phenotype Acute Leukemia (MPAL) mugihe ivuwe na B-BYOSE chimiotherapie. Izindi ntego z’ubu bushakashatsi zirimo gukora iperereza niba kuvura abagabo n’igitsina gore igihe kimwe cya chimiotherapie bikomeza ibisubizo ku bagabo bavuwe mbere y’umwaka w’inyongera ugereranije n’abakobwa, ndetse no gusuzuma uburyo bwiza bwo gufasha abarwayi kubahiriza umunwa imiti ya chimiotherapie. Hanyuma, ubu bushakashatsi buzaba ubwambere mugukurikirana ibyavuye mumasomo akwirakwizwa na B-selile Lymphoblastique Leukemia (B LLy) cyangwa ivangwa rya Phenotype Acute Leukemia (MPAL) mugihe ivuwe na B-BYOSE chimiotherapie.
Aho uherereye: 189
Byihuta cyangwa bisanzwe BEP Chimoterapi mu kuvura abarwayi bafite ibibyimba bito cyangwa bidakabije-Ibyago byo mu ngirabuzimafatizo yo mu Budage
Iki cyiciro cya gatatu cyateganijwe cyiga uburyo gahunda yihuse ya sulfate ya bleomycine sulfate, etoposide fosifate, na cisplatine (BEP) ya chimiotherapie ikora ugereranije na gahunda isanzwe ya chimiotherapie ya BEP mukuvura abarwayi bafite ibibyimba biterwa na mikorobe byanduye bikabije bikwirakwira mubindi ahantu mu mubiri (metastatike). Ibiyobyabwenge bikoreshwa muri chimiotherapie, nka sulfate ya bleomycine, fosifate ya etoposide, na cisplatine, bikora muburyo butandukanye bwo guhagarika imikurire ya selile yibibyimba, haba mukwica selile, kubabuza gutandukana, cyangwa kubabuza gukwirakwira. Gutanga chimiotherapie ya BEP kuri gahunda yihuse, cyangwa "yihuse" irashobora gukora neza hamwe ningaruka nkeya mukuvura abarwayi bafite ibibyimba byo hagati ya mikorobe mito cyangwa ibyago bike ugereranije na gahunda isanzwe.
Aho uherereye: ahantu 139
Emera igitekerezo auto-refresher